The Prognostic Value of Preoperative C-Reactive Protein Levels in Resected Early-Stage Lung Cancer

被引:0
作者
Lopez-Pastorini, Alberto [1 ,2 ,4 ,5 ]
Tatli, Zehra [3 ]
von Bargen, Antonia [2 ]
Faltenberg, Dennis [2 ]
Beling, Hendrik [3 ]
Galetin, Thomas [1 ,2 ,6 ]
Koryllos, Aris [1 ,2 ,6 ]
Stoelben, Erich [1 ,3 ,7 ]
机构
[1] Witten Herdecke Univ Hosp, Cologne Merheim Hosp, Dept Thorac Surg, Cologne, Germany
[2] Witten Herdecke Univ, Fac Med, Witten, Germany
[3] Univ Cologne, Fac Med, Cologne, Germany
[4] Univ Cologne, Fac Med, Dept Gen Visceral Thorac & Transplantat Surg, Kerpener Str 62, D-50937 Cologne, Germany
[5] Univ Cologne, Univ Hosp Cologne, Kerpener Str 62, D-50937 Cologne, Germany
[6] Florence Nightingale Hosp, Dept Thorac Surg, Dusseldorf, Germany
[7] St Hildegardis Hosp, Dept Thorac Surg, Cologne, Germany
关键词
Biomarkers; C -reactive protein; Lung cancer; Prognosis; SYSTEMIC INFLAMMATION; ASSOCIATION; SURVIVAL; INTERLEUKIN-6; POPULATION; IMPACT;
D O I
10.1016/j.jss.2024.11.003
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: C-reactive protein (CRP) is the most widely used marker of the systemic inflammatory response. An association between preoperative elevated levels and prognosis has been demonstrated for numerous tumors. The aim of this study was to investigate the association between preoperative CRP levels and survival in early-stage nonsmall cell lung cancer. Methods: Data from 915 consecutive patients who underwent complete resection for stage I and II nonsmall cell lung cancer were retrospectively analyzed. Recurrence-free survival (RFS) and overall survival (OS) according to preoperative CRP levels were evaluated by the Kaplan-Meier method. The Cox proportional hazards model and logistic regression analysis were used for multivariate analysis. Results: Five-year RFS and OS were 61.0% and 70.3% in the low CRP group (<4 mg/L) and 41.8% and 49.4% in the high CRP group (>= 4 mg/L), respectively (P < 0.001). In univariate analysis, CRP levels were correlated with indicators of tumor burden and pulmonary co- morbidity. In multivariate analysis, CRP levels were identified as an independent predictor of RFS and OS. Conclusions: Elevated preoperative CRP is associated with poor prognosis in patients with early-stage lung cancer. CRP may guide risk-adapted follow-up and adjuvant therapy decisions. As CRP elevation is also associated with nontumor related conditions patients need to be screened for coexisting comorbidities. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:85 / 92
页数:8
相关论文
共 31 条
[1]   Interaction between non-small-cell lung cancer cells and fibroblasts via enhancement of TGF-β signaling by IL-6 [J].
Abulaiti, Abulimiti ;
Shintani, Yasushi ;
Funaki, Soichiro ;
Nakagiri, Tomoyuki ;
Inoue, Masayohi ;
Sawabata, Noriyoshi ;
Minami, Masato ;
Okumura, Meinoshin .
LUNG CANCER, 2013, 82 (02) :204-213
[2]   Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer [J].
Alifano, Marco ;
Falcoz, Pierre E. ;
Seegers, Valerie ;
Roche, Nicolas ;
Schussler, Olivier ;
Younes, Mohamad ;
Antonacci, Filippo ;
Forgez, Patricia ;
Dechartres, Agnes ;
Massard, Gilbert ;
Damotte, Diane ;
Regnard, Jean-Francois .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2011, 142 (05) :1161-1167
[3]   Inflammation and outcome after general thoracic surgery [J].
Amar, David ;
Zhang, Hao ;
Park, Bernard ;
Heerdt, Paul M. ;
Fleisher, Martin ;
Thaler, Howard T. .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2007, 32 (03) :431-434
[4]  
Argiles J M, 2005, Eur J Oncol Nurs, V9 Suppl 2, pS39, DOI 10.1016/j.ejon.2005.09.006
[5]   C-Reactive Protein and Breast Cancer: New Insights from Old Molecule [J].
Asegaonkar, Shilpa Balaji ;
Asegaonkar, Balaji Narayanrao ;
Takalkar, Unmesh Vidyadhar ;
Advani, Suresh ;
Thorat, Anand Pandurang .
INTERNATIONAL JOURNAL OF BREAST CANCER, 2015, 2015
[6]   Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy [J].
Chang, Chin Hao ;
Hsiao, Chin Fu ;
Yeh, Yu Min ;
Chang, Gee Chen ;
Tsai, Ying Huang ;
Chen, Yuh Min ;
Huang, Ming Shyan ;
Chen, Hui Ling ;
Li, Yao Jen ;
Yang, Pan Chyr ;
Chen, Chien Jen ;
Hsiung, Chao A. ;
Su, Wu Chou .
INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (09) :1977-1985
[7]   Systemic inflammation and decline in lung function in a general population: a prospective study [J].
Fogarty, Andrew W. ;
Jones, Stuart ;
Britton, John R. ;
Lewis, Sarah A. ;
McKeever, Tricia M. .
THORAX, 2007, 62 (06) :515-520
[8]   Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis [J].
Gan, WQ ;
Man, SFP ;
Senthilselvan, A ;
Sin, DD .
THORAX, 2004, 59 (07) :574-580
[9]   Tumor necrosis factor In lung cancer: Complex roles in biology and resistance to treatment [J].
Gong, Ke ;
Guo, Gao ;
Beckley, Nicole ;
Zhang, Yue ;
Yang, Xiaoyao ;
Sharma, Mishu ;
Habib, Amyn A. .
NEOPLASIA, 2021, 23 (02) :189-196
[10]   Inflammation and Cancer: Triggers, Mechanisms, and Consequences [J].
Greten, Florian R. ;
Grivennikov, Sergei, I .
IMMUNITY, 2019, 51 (01) :27-41